Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer

Table 1 Patient and tumor characteristics (n = 119)

	Median	Range
Age at diagnosis (yr)	61	33-84
Age at MMC/capecitabine onset (yr)	64	37-85
Previous treatment duration (yr)	2.03	0.2-9.3
	n	Valid %1
Male gender	68	57.1
Smoking history	33	30.6
Ethnicity
Jewish Ashkenazi	61	51.3
Other	58	48.7
Family history of cancer
Any	67	67.7
GI	32	32.3
Synchronous metastatic disease	82	68.9
Liver metastases	97	81.5
Tumor grade
Well-moderate	85	71.4
Poor	34	28.6
Tumor location
Right colon	29	24.4
Left colon	90	75.6
KRAS mutation	44	44.4
NRAS mutation	3	7.5
BRAF mutation	1	5.3
MSI-H/ MMRd	2	7.4
MMC/capecitabine line
3rd	50	42.0
4th	35	29.4
Subsequent	34	28.6
Previous drug exposure
Oxaliplatin	119	100.0
Irinotecan	118	99.2
5-FU	118	99.2
Capecitabine	14	11.8
Bevacizumab	109	91.6
Cetuximab/panitumumab	51	42.9
Regorafenib	14	11.8
TAS-102	7	5.9
ECOG PS
0-1	70	58.8
> 1	49	41.2

¹Data were missing on smoking (11 patients), family history (20), KRAS (20), NRAS (79), BRAF (100), and MSI/MMR (92).

N: Number; MMC: Mitomycin C; GI: Gastrointestinal; MSI: Microsatellite instability; MMRd: Mismatch repair deficient; ECOG PS: Eastern cooperative oncology group performance status; 5-FU: 5-fluorouracil.